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Abstract
Spontaneous bacterial peritonitis (SBP) is a frequent, 
life-threatening bacterial infection in patients with 
liver cirrhosis and ascites. Portal hypertension leads 
to increased bacterial translocation from the intestine. 
Failure to eliminate invading pathogens due to immune 
defects associated with advanced liver disease on the 
background of genetic predisposition may result in SBP. 
The efficacy of antibiotic treatment and prophylaxis has 
declined due to the spread of multi-resistant bacteria. 
Patients with nosocomial SBP and with prior antibiotic 
treatment are at a particularly high risk for infection 
with resistant bacteria. Therefore, it is important to 
adapt empirical treatment to these risk factors and to 
the local resistance profile. Rifaximin, an oral, non-
absorbable antibiotic, has been proposed to prevent 
SBP, but may be useful only in a subset of patients. 
Since novel antibiotic classes are lacking, we have to 
develop prophylactic strategies which do not induce 
bacterial resistance. Farnesoid X receptor agonists 
may be a candidate, but so far, clinical studies are not 
available. New diagnostic tests which can be carried 
out quickly at the patient’s site and provide additional 
prognostic information would be helpful. Furthermore, 
we need tools to predict antibiotic resistance in order 
to tailor first-line antibiotic treatment of spontaneous 
bacterial peritonitis to the individual patient and to 
reduce mortality.
Key words: Ascites; Cirrhosis; Farnesoid X receptor; 
Liver; Nucleotide-binding oligomerization domain 
containing 2; Rifaximin; Prophylaxis; Spontaneous 
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Core tip: Spontaneous bacterial peritonitis (SBP) is a 
frequent infection in patients with liver cirrhosis which 
is associated with a poor prognosis. Portal hypertension 
leads to translocation of intestinal bacteria which cannot 
be eliminated due to immune defects caused by liver 
cirrhosis and genetic predisposition. Empirical antibiotic 
treatment has become less effective because of wide-
spread antibiotic resistance. This review summarises key 
features of SBP and points out how diagnosis, treatment 
and prophylaxis may be improved in the future in order 
to reduce mortality.
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INTRODUCTION
Patients in advanced stages of liver cirrhosis tend to 
develop bacterial peritonitis without evident source of 
infection, a form of infection which has been termed 
spontaneous bacterial peritonitis (SBP) in 1963[1]. Next 
to urinary tract infection, SBP is the most frequent 
infection in patients with advanced liver cirrhosis[2]. 
While it develops in up to 3.5% of patients that are 
treated as outpatients[3], its prevalence is as high as 
12% in hospitalized patients[2,4]. In patients at high 
risk, SBP incidence can be reduced by prophylactic 
antibiotic treatment[5-7]. However, efforts to decrease 
the high mortality associated with SBP, ranging 
between 16% and 52%, had to face disappointing 
limitations[2,8,9] Concerning antibiotic treatment 
and prophylaxis, the rise of bacterial resistance to 
antibiotics commonly used in patients with liver 
cirrhosis has reduced the therapeutical options[10]. 
In addition, attempts to decrease the prevalence 
of the indispensable underlying condition of SBP, 
liver cirrhosis, by modern antiviral treatment of viral 
hepatitis B and C, will probably be counterbalanced by 
the rising number of patients with non-alcoholic fatty 
liver disease[11]. Furthermore, SBP is recognised as an 
important marker of liver disease progression which 
might be the decisive watershed in the management 
of advanced liver disease[12]. It can be conceived 
as the clinically evident manifestation of bacterial 
translocation from the intestine, linking intestinal 
microbiome, genetic and acquired immune defects 
to the development of infection. Thus, SBP stays not 
only at the centre of liver disease pathophysiology, 
but also remains a challenge in clinical management. 
Neither reduction of the burden of liver disease nor 
development of new antibiotics to overcome bacterial 
resistance will occur in near future. Therefore, the 
challenge is to define subgroups of patients for optimal 
therapy in order to decrease failure of empirical 
therapy and exert low selection pressure on bacteria.
LEAKY GUT
The usual bacteria causing SBP in patients without 
prior antibiotic treatment or frequent hospitalisations 
are enteric bacteria, mostly Escherichia coli (E. coli)[13,14]. 
Upper gastrointestinal bleeding is the only major risk 
factor with sudden onset[15]. Usually, an external source 
of infection cannot be identified[16]. Taken together, 
these facts suggest that SBP is an endogenous 
infection, in general caused by transmigration of 
enteric bacteria to the ascites[17]. 
Apart from these clinical observations, experimental 
data also support this hypothesis. Bacterial trans-
location of enteric bacteria to mesenterial lymph nodes 
was not only observed in animal models[18,19], but also 
in patients with liver cirrhosis, in whom the prevalence 
of bacterial translocation increased with liver disease 
severity assessed by the Child-Pugh-Score[20]. In 
addition, indirect signs of bacterial translocation, such 
as elevated levels of lipopolysaccharide binding protein 
(LBP)[21] or bacterial DNA[22] are frequently found in 
patients with liver cirrhosis. 
Nevertheless, bacteria from other sources are also 
found in ascites. Pyrosequencing of ascitic DNA for 
viable bacteria revealed that a substantial amount 
of non-enteric bacteria have access to the peritoneal 
cavity[23]. In patients, SBP may be caused by bacteria 
not known from the intestine: examples like SBP by 
Pasteurella multocida after a scratch of a pet dog[24] 
or in a pet holder[25] and SBP by bacillus cereus[26] 
indicate that any kind of bacteremia in cirrhotic 
patients might end up in ascites infection. In addition, 
a recent study in Chinese patients suggested that the 
intestinal microbiome of patients with liver cirrhosis, 
in contrast to healthy controls, might contain bacteria 
which normally reside in the oral cavity[27]. Therefore, 
it is difficult to distinguish the source of infection by 
identifying the causative microorganism. It is not 
known to which extent different routes of infection 
contribute to the development of SBP.
In general, intestinal bacterial translocation is 
conceived as a key feature of liver cirrhosis[17]. However, 
measuring bacterial translocation directly is not feasible, 
so surrogate parameters like lipopolysaccharide (LPS) 
- a component of the wall of Gram-negative bacteria 
- bacterial DNA or LPS binding protein (LBP) are 
used[28]. In animal models, elevated levels of LPS or 
LBP can be induced by liver damage[29,30]. Markers of 
bacterial translocation have been linked to all major 
complications of liver cirrhosis, including ascites 
formation[21], severe portal hypertension[31], variceal 
bleeding[32], hepatorenal syndrome, SBP[33] and hepatic 
encephalopathy[34]. Three factors are considered as 
key mechanisms to increase bacterial translocation in 
patients with liver cirrhosis: changes in the amount 
and composition of the intestinal microbiome[35], a 
decreased barrier function of the intestine[36] and 
impaired host responses to translocating bacteria[37].
In healthy subjects, the small bowel contains a 
relatively small number of bacteria[38]. By contrast, 
in patients with liver cirrhosis, bacterial overgrowth 
in the small bowel occurs[39,40] . With the advances in 
microbiome research, the composition of intestinal 
bacteria in patients with liver cirrhosis can now 
be assessed in more detail. Significant differences 
compared to healthy subjects have been found[27]. In 
addition, it is not only the bacterial species present 
in the intestine that may lead to complications of 
liver cirrhosis[41], but also the products of bacterial 
metabolism. In line with this, intake of rifaximin 
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improves cognition along with altering metabolites 
from intestinal bacteria, but does not influence the 
composition of the intestinal microbiome[42]. An 
intriguing question is in how far the intestinal micro-
biome is only the consequence of liver disease or - once 
pathologically changed - contributes to the development 
of more severe disease[35].
It is important to note that the virulence of bacterial 
strains concerning onset and course of infection differs 
considerably. E. coli strains causing SBP display higher 
motility than E. coli causing urinary or biliary tract 
infections[43]. In addition, SBP by encapsulated E. coli 
is associated with more complications[44] and in the 
special case of the K1 antigen with lower survival[45]. 
A decreased barrier function of the intestine in 
advanced liver disease has been found in animal 
models[46-48] and humans[31,49,50]. Recently, the farnesoid 
X receptor (FXR), a nuclear receptor for bile acids[51], 
has emerged as an important molecule for maintaining 
the intestinal barrier. Bacterial translocation from the 
intestine is increased in FXR knock-out and in bile-
duct ligated mice[52]. Synthetical FXR agonists block 
bacterial translocation in the latter[52] and decrease 
portal hypertension in animals models of cirrhosis[53]. 
In addition, a FXR polymorphism which leads to a 
reduced translation of FXR target genes is associated 
with the occurrence of SBP[54]. So far, it is not known 
if synthetic FXR agonists may reduce bacterial trans-
location in humans.
SBP is associated with polymorphisms in pattern 
recognition receptors, for example the nucleotide-
binding oligomerization domain containing 2 (NOD2) 
gene[55,56]. The same NOD2 polymorphisms predispose 
for Crohn’s disease[57], which is also characterised by 
a leaky gut. Unfortunately, the mechanism by which 
these polymorphisms lead to increased bacterial 
translocation is still debated. Nevertheless, this 
joint association provides a clear hint for a shared 
mechanism and underlines the involvement of the 
innate immune system in bacterial translocation.
CIRRHOTIC LIVER
Portal hypertension is a hallmark of advanced liver 
cirrhosis. Decreasing portal hypertension reduces 
bacterial translocation[31]. However, data on a possibly 
protective role of non-selective beta blockers, which 
reduce portal pressure, concerning the occurrence of 
SBP in patients with liver cirrhosis are contradictory[12,58]. 
Another treatment for portal hypertension is the 
placement of a transjugular intrahepatic portosystemic 
shunt (TIPS)[59]. A meta-analysis on TIPS for refractory 
ascites found no signficantly decreased incidence of SPB 
in patients with TIPS[60], but studies focussing directly 
on this issue are missing. 
Apart from portal hypertension, cirrhosis leads 
to the development of various immune defects and 
might unmask minor genetic immune defects. The 
importance of genetic predisposition is stressed by 
the high recurrence rate of SBP after a first episode 
if no antibiotic prophylaxis is given. In addition to 
polymorphisms in the NOD2[55,56] gene, which have 
not only been linked to an impaired intestinal barrier 
but also to altered innate immune responses[57], 
polymorphisms in the toll-like receptor 2 (TLR2) gene[61] 
and the monocyte chemotactic protein 1 (MCP1) 
gene[62,63] have been associated with the occurrence of 
SBP. TLR2 and NOD2 are pattern recognition receptors 
that sense bacterial components and trigger immune 
responses[64]. Patients carrying both a NOD2 and a 
TLR2 risk variant have a particularly high susceptibility 
for SBP[61]. Overall, patients with liver cirrhosis and 
ascites carrying a NOD2 risk variant display a higher 
mortality than patient with wild-type alleles[55,56]. MCP1 
is a chemokine attracting immune cells, in particular 
monocytes, to the site of infection[65]. Monocytes from 
patients with the G allele at position -2518 produce 
more MCP1 than monocytes from patients with the 
A allele at this position[66], so that patients with the 
A allele are probably more prone to SBP because 
of a deficit to raise adequate levels of MCP1. Taken 
together, these genetic studies point at an eminent 
role of the innate immune system in the development 
of SBP. Determination of these polymorphisms has no 
diagnostic impact, because not all patients carrying 
these mutations will develop SBP, probably due to 
the presence of so far unknown protective genetic 
variations and competing risk factors, e.g. death from 
variceal bleeding or hepatocellular carcinoma. In 
addition, the presence of these polymorphisms does 
not predict the onset of SBP - while some patients will 
develop SBP at first decompensation, other patients 
receive several large-volume paracentesis till SBP 
occurs. 
Synthesis of proteins by a cirrhotic liver is reduced 
and fluid accumulates, leading to lower ascites 
protein concentration, which has been described as 
one of the major risk factors for SBP[6,7]. In addition, 
defects in neutrophil[67], monocyte[68], T cell[69] and 
dendritic cell[70] function have been shown in patients 
with liver cirrhosis. It is probable that these immune 
defects impair the normal clearance of translocated 
bacteria, leading to a state of permanent immune 
activation and inflammation[21]. The most common 
causes of liver cirrhosis, viral hepatitis and alcoholic 
abuse, differ by the mechanisms of liver damage. 
However, studies demonstrating differences in immune 
function of ascites cells between these two etiologies 
are rare. One study found that ascites macrophages 
are more pro-inflammatory in alcoholic liver disease 
than in liver cirrhosis induced by hepatitis C virus[71]. 
Nevertheless, the scarcity of such studies rather seems 
to indicate that alterations in the immune system 
concerning the susceptibility to bacterial infections in 
chronic liver disease are determined mainly by liver 
failure in general, while the cause of liver disease is 
secondary.
Although many aspects of bacterial translocation 
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with poor prognosis[79]. However, reliable determination 
of resistance profiles can so far only be done by pheno­
typical tests after conventional culture.
One of the advantages of the current diagnostic 
definition of SBP is its simplicity. However, a differential 
leukocyte count of the ascites can be obtained only 
in some clinical settings. Therefore, alternative tests 
that can be performed easily, rapidly and reliably are 
needed. The most advanced form of these tests is a 
urinary dipstick that is calibrated especially to ascites[80]. 
Calprotectin, a protein secreted by neutrophils, is 
another candidate for a bedside test[81].
TREATMENT OF SBP 
Antibiotic therapy for 5 d with third generation 
cephalosporines is the established treatment for 
SBP[6,7]. Randomised trials concerning the antibiotic 
treatment of SBP are summarised in Table 2. In 
addition to antibiotics, substitution of albumin to 
prevent occurrence of hepatorenal syndrome is 
recommended, in particular for patients that present 
with total bilirubin > 4 mg/dL or creatinine > 1 mg/dL 
or urea nitrogen > 30 mg/dL[7]. Treatment with albumin 
reduces the incidence of renal failure and death[82]. 
However, the rise in bacterial resistance has reduced 
the efficacy of third generation cephalosporines and 
quinolones, especially in nosocomial infections[78]. 
In addition, enterococci, which are per se resistant 
to cephalosporines, have become more frequent as 
a source of SBP[83]. Failure of first line treatment is 
associated with worse survival[84]. Therefore, it would 
be necessary to replace cephalosporines with a more 
effective empiric therapy. The regional variability of 
antibacterial resistance limits a general approach. 
Considering isolates from culture-positive SBP, only 
combinations of modern broad spectrum antibiotics 
like carbapenems and glykopeptides are considered as 
reliably effective first line therapy in all patients[78,85]. 
Renal toxicity, costs and concerns about induction 
of even more multi-resistant microorganisms are 
drawbacks of such a treatment. First results of a 
randomised trial comparing ceftazidime vs meropenem 
+ daptomycin (NCT01455246) presented at the 
congress of the American Association for the Study of 
Liver Diseases 2014 (poster 574)[86] indicate a benefit 
for the combination therapy.
Therefore, it seems more adequate to identify risk 
factors for resistance to standard treatment in order 
to select patients who profit from broader antibiotic 
treatment. Known risk factors are nosocomial infection, 
previous antibiotic prophylaxis with norfloxacin, use 
of beta-lactams during the past 12 wk and a history 
of infection by multi-resistant bacteria[10]. For patients 
with these risk factors, treatment adapted to the 
local resistance profiles is recommended. However, 
therapy should be started immediately after diagnosis 
of SBP, and most clinicians might not know the local 
resistance profiles. A more general recommendation is 
are known, it is still not fully understood how and when 
bacterial translocation finally leads to SBP. Important 
risk factors for SBP are listed in Table 1.
DIAGNOSIS OF SBP
This limitation in our understanding led to simplified 
diagnostic criteria, which are easy to use in clinical 
practice, but may not reflect differences in disease. 
Diagnosis of SBP is made according to international 
guidelines[6,7] in patients with liver cirrhosis if the 
ascites polymorphonuclear (PMN) cell count exceeds 
250 cells/μL and other forms of peritonitis have 
been excluded. Among others, differential diagnosis 
comprises malignant ascites, bowel perforation, 
intraabdominal abscess formation, pancreatitis and 
peritonitis due to special bacteria like mycobacterium 
tuberculosis or chlamydia. Hints for secondary bacterial 
peritonitis due to bowel perforation are polymicrobial 
culture growth in combination with two of the following 
findings in the ascites: a total protein above 1 g/dL, 
lactate dehydrogenase above the normal for serum 
and glucose levels below 50 mg/dL[7]. 
A PMN count of 250 cells/μL has been chosen 
because it constitutes a sensitive diagnostic marker[16]. 
Growth of bacteria in the ascites culture does 
not establish the diagnosis of SBP, since bacteria 
are detected only in about 40% of SBP cases[6,9]. 
Conversely, detectable bacteria in ascites samples 
with a PMN count below 250 cells/μL lead only in 
38% to SBP, because most patients eliminate the 
bacteria without therapeutic intervention[72]. Attempts 
to improve the sensitivity of microbiological ascites 
analysis had limited success. Overall, detection of 
bacteria in the ascites by PCR-based methods failed 
to improve test accuracy[73-76]. A pilot study using 
in-situ hybridisation in ascites leukocytes detected 
bacteria in 10/11 SBP cases, but this study is limited 
by the small sample size and by the fact that species 
identification was not possible[77]. However, even if a 
molecular method could prove superior to traditional 
culture methods regarding detection rate, a problem of 
increasing importance is rapid detection of resistance 
to antibiotics[78], since failure of first­line treatment due 
to increasing rates of bacterial resistance is associated 
Table 1  Important risk factors for spontaneous bacterial 
peritonitis
  Variceal bleeding[15]
  Previous SBP[6]
  Genetic polymorphisms in the NOD2[55,56], TLR2[61], MCP1[62,63] 
  and FXR[54] gene
  Low ascites protein content (below 1-1.5 g/dL)[7]
  Advanced liver disease[116]
  Intake of proton pump inhibitors[96,97]
SBP: Spontaneous bacterial peritonitis; NOD2: Nucleotide-binding 
oligomerization domain containing 2; TLR2: Toll like receptor 2; MCP1: 
Monocyte chemotactic protein 1; FXR: Farnesoid X receptor.
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to give piperacillin/tazobactam or - in regions with high 
prevalence of multi-resistant bacteria - carbapenems 
in combination with glykopeptides[78]. In addition, a 
second paracentesis after 48 h of treatment should 
be performed[6]. Based on the results from a first 
study, a decrease of less than 25% of PMN indicates 
treatment failure and should prompt a change in 
treatment[6]. Recognizing treatment failure as early 
as possible is essential to reduce mortality. Thus, 
studies to define more and better parameters of 
treatment response are needed. Of course, rapid 
microbiological analysis and communication of the 
results to the clinician is another important factor to 
guide therapy. However, it is not only response to 
antibiotic treatment that reduces mortality, but also 
prevention of renal failure, which might be the most 
important prognostic factor[8,87]. Albumin substitution 
to prevent renal failure in the context of SBP was 
already discussed above.
In summary, the challenges of SBP therapy are 
various given the rise in resistant bacteria. New classes 
of antibiotics need to be developed. More knowledge 
about distinguishing patients who can be treated with 
standard antibiotics from those who need special 
treatment is required. Last but not least, failure of 
first line treatment must be detected as early and as 
reliably as possible. Still, effective prophylaxis of SBP 
might alleviate all these problems.
PROPHYLAXIS OF SBP
Primary and secondary prophylaxis of SBP has 
been established based on some of the known risk 
factors for SBP: gastrointestinal bleeding, previous 
SBP and low ascites protein content[6,7]. Primary 
prophylaxis of SBP is recommended in all patients 
with gastrointestinal bleeding and mostly done 
with cephalosporines[78,88]. In this context, antibiotic 
prophylaxis has been reported to reduce SBP incidence 
about 70%[89]. Low ascites protein content has been 
identified early on as risk factor for SBP[90], which 
has been explained by a low complement activity[91]. 
A randomised controlled trial[92] in 68 patients with 
low ascites protein and advanced liver failure or 
impaired renal function showed that prophylaxis with 
norfloxacin significantly reduced the occurrence of SBP 
and improved 3-mo survival, so that primary antibiotic 
prophylaxis for such patients should be considered 
according to current guidelines[6,7]. So far, no study 
has investigated if the rise in resistant bacteria 
counterbalances the benefit of primary prophylaxis in 
these patients. 
Secondary prophylaxis of SBP with quinolones 
is widely recommended[6,7] based on the result of a 
clinical trial[93] and data from studies including patients 
with and without prior SBP[5,94]. However, an increase 
of infections with quinolone - resistant bacteria has 
been reported after the introduction of secondary 
prophylaxis into clinical practice[10,95]. Again, data from 
randomised trials to evaluate the efficacy of secondary 
prophylaxis in the context of a high prevalence of 
antibiotic resistance are missing. Naturally, long term 
prophylaxis has to be carried out with oral antibiotics, 
so that not only parenteral, but also oral new antibiotic 
classes are needed. Randomised studies on primary 
and secondary antibiotic prophylaxis of SBP are 
summarized in Table 3.
Most risk factors for SBP cannot be modified 
easily. However, use of acid suppressive therapy, 
in particular with proton pump inhibitors, has been 
shown to increase the risk for SBP[96,97]. Therefore, 
acid suppressive therapy should be prescribed only if 
a clear indication exists, which is not often the case[84]. 
Interestingly, this harmful side-effect of proton pump 
inhibitors seems to be caused rather by impaired 
oxidative burst of granulocytes and monocytes[98] 
than by inducing small bowel bacterial overgrowth[99]. 
Probiotics can reduce bacterial translocation and the 
associated inflammatory changes in animal models 
of liver cirrhosis[100,101]. However, clinical trials did not 
show a significant reduction of SBP incidence under 
treatment with probiotics[102,103].
A new approach for SBP prophylaxis is to consider 
non-absorbable antibiotics that might reduce the 
intestinal bacterial load without systemic side effects[16]. 
The main candidate is rifaximin[104], which prevents 
Table 2  Randomised controlled trials concerning antibiotic treatment of spontaneous bacterial peritonitis
  Ref. No. of 
patients
Study arms Resolution of 
infection
P Comment
  Felisart et al[117]   73 Ampicillin + tobramycin vs cefotaxime 56% vs 85% < 0.02 Also patients without SBP 
included
  Rimola et al[118] 143 Cefotaxime 8 g/24 h vs 4 g/24 h 77% vs 79% NS
  Navasa et al[119] 123 Ofloxacin po vs cefotaxime iv 84% vs 85% NS Only patients with 
uncomplicated SBP included
  Ricart et al[120]   48 Amoxicillin-clavulanic acid vs cefotaxime 88% vs 83% NS
  Terg et al[121]   80 Ciprofloxacin only iv vs 2 d iv then po 76 vs 78% NS
  Piano et al[86]
  (NCT01455246)
  (preliminary results presented 
  at the AASLD 2014, Abstract 574)
  32 Daptomycin + meropenem vs ceftazidime 87% vs 25% < 0.001 Only patients with 
nosocomial SBP included
NS: Not significant; SBP: Spontaneous bacterial peritonitis.
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hepatic encephalopathy[105,106] and is widely used in 
patients with liver cirrhosis. In addition, it belongs 
to a class of antibiotics which is normally not used in 
therapy of SBP and was originally reported to induce 
no bacterial resistance[107]. A small study reported 
that patients who responded to rifaximin treatment 
by reduction of hepatic venous pressure gradient 
displayed a significant reduced rate of complications 
from liver cirrhosis including SBP over 5 years of 
follow-up[108]. Another retrospective study comprising 
404 patients with liver cirrhosis and ascites requiring 
paracentesis described a significant reduction of SBP 
by rifaximin. However, patients with prior SBP or SBP 
occurring in the course of gastrointestinal bleeding 
had been excluded[109]. In addition, a prospective 
observational study of 152 patients with advanced 
liver cirrhosis found a reduction of SBP incidence only 
by quinolones, but not by rifaximin[110]. The different 
results of these studies may be explained by variations 
in the risk for SBP and severity of liver disease, 
suggesting that rifaximin might be effective only in 
the subgroup of patients who have relatively low risk 
for SBP and less severe liver disease. In summary, 
rifaximin cannot be recommended for SBP prophylaxis 
until prospective, randomised studies are available.
An ongoing clinical trial investigates if primary 
antibiotic prophylaxis with quinolones is beneficial 
in patients with a genetically determined high risk 
(EudraCT number 2013-001626-26).
Nevertheless, all antibiotics, including rifaxi-
min[111-113], will lead to the emergence of bacterial 
resistance. Therefore, strategies avoiding the use of 
antibiotics might be more promising on the long term. 
Potential candidates are FXR agonists, since reduced 
FXR function is associated with increased bacterial 
translocation[52,54]. FXR agonist have already been 
tested for non-alcoholic fatty liver disease and primary 
biliary cirrhosis and show a good safety profile[114,115]. 
Thus, this new class of drugs may become a novel tool 
to decrease bacterial translocation in the future.
CONCLUSION
SBP occurs frequently in patients with liver cirrhosis, 
because liver disease leads to increased rates of 
bacterial translocation from the gut, but is also 
associated with a compromised immune system. 
Mortality of SBP has remained high and bacterial 
resistance to antibiotics threatens to increase 
mortality even more in the future. The challenge is 
to improve treatment efficacy by understanding the 
pathophysiology of SBP in more detail, by tailoring the 
therapy to the needs of the individual patient and by 
identifying new approaches for prophylaxis.
REFERENCES
1 Conn HO. Spontaneous peritonitis and bacteremia in laennec’s 
cirrhosis caused by enteric organisms. a relatively common but 
rarely recognized syndrome. Ann Intern Med 1964; 60: 568-580 
[PMID: 14138877 DOI: 10.7326/0003-4819-60-4-568]
2 Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital 
mortality trends of infections among patients with cirrhosis: a 
nationwide study of hospitalised patients in the United States. 
Aliment Pharmacol Ther 2014; 40: 105-112 [PMID: 24832591 
DOI: 10.1111/apt.12797]
3 Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous 
bacterial peritonitis in asymptomatic outpatients with cirrhotic 
ascites. Hepatology 2003; 37: 897-901 [PMID: 12668984 DOI: 
10.1053/jhep.2003.50119]
4 Cadranel JF, Nousbaum JB, Bessaguet C, Nahon P, Nguyen-Khac 
E, Moreau R, Thévenot T, Silvain C, Bureau C, Nouel O, Pilette C, 
Paupard T, Pauwels A, Sapey T, Grangé JD, Tran A. Low incidence 
of spontaneous bacterial peritonitis in asymptomatic cirrhotic 
outpatients. World J Hepatol 2013; 5: 104-108 [PMID: 23556041 
DOI: 10.4254/wjh.v5.i3.104]
5 Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic 
prophylaxis reduces spontaneous bacterial peritonitis occurrence 
and improves short-term survival in cirrhosis: a meta-analysis. Am 
J Gastroenterol 2009; 104: 993-1001; quiz 1002 [PMID: 19277033 
DOI: 10.1038/ajg.2009.3]
6 European Association for the Study of the Liver. EASL clinical 
practice guidelines on the management of ascites, spontaneous 
bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J 
Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/
j.jhep.2010.05.004]
7 Runyon BA. Introduction to the revised American Association 
for the Study of Liver Diseases Practice Guideline management of 
adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 
57: 1651-1653 [PMID: 23463403 DOI: 10.1002/hep.26359]
8 Tandon P, Garcia-Tsao G. Renal dysfunction is the most important 
independent predictor of mortality in cirrhotic patients with 
spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011; 
9: 260-265 [PMID: 21145427 DOI: 10.1016/j.cgh.2010.11.038]
9 Tandon P, Kumar D, Seo YS, Chang HJ, Chaulk J, Carbonneau 
M, Qamar H, Keough A, Mansoor N, Ma M. The 22/11 risk 
prediction model: a validated model for predicting 30-day mortality 
in patients with cirrhosis and spontaneous bacterial peritonitis. Am 
J Gastroenterol 2013; 108: 1473-1479 [PMID: 23877350 DOI: 
Table 3  Randomised controlled trials concerning antibiotic prophylaxis of spontaneous bacterial peritonitis
  Ref. No. of patients Study arms Kind of prophylaxis Occurence of SBP P
  Ginés et al[93]   80 Norfloxacin vs placebo Secondary 12% vs 35% 0.014
  Soriano et al[122]   63 Norfloxacin vs control Primary/secondary 0% vs 23% < 0.05
  Singh et al[123]   60 Trimethoprim-sulfamethoxazole vs control Primary/secondary 3% vs 27% 0.025
  Grangé et al[124] 107 Norfloxacin vs placebo Primary 0% vs 9% NS
  Rolachon et al[125]   60 Ciprofloxacin vs placebo Primary/secondary 4% vs 22% < 0.05
  Novella et al[126] 109 Norfloxacin permanently vs only during hospitalisation Primary 2% vs 17% < 0.01
  Fernández et al[92]   68 Norfloxacin vs placebo Primary 7% vs 61% < 0.001
  Terg et al[127] 100 Ciprofloxacin vs placebo Primary 4% vs 14% 0.076
NS: Not significant; SBP: Spontaneous bacterial peritonitis.
Lutz P et al . Spontaneous bacterial peritonitis: Clinical challenges
310 March 27, 2015|Volume 7|Issue 3|WJH|www.wjgnet.com
10.1038/ajg.2013.204]
10 Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca 
D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi 
F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of 
infections by multiresistant bacteria in cirrhosis: a prospective 
study. Hepatology 2012; 55: 1551-1561 [PMID: 22183941 DOI: 
10.1002/hep.25532]
11 Karlas T, Wiegand J, Berg T. Gastrointestinal complications of 
obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. 
Best Pract Res Clin Endocrinol Metab 2013; 27: 195-208 [PMID: 
23731881 DOI: 10.1016/j.beem.2013.02.002]
12 Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, 
Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-
Radosavljevic M, Reiberger T. Nonselective β blockers increase 
risk for hepatorenal syndrome and death in patients with cirrhosis 
and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 
1680-90.e1 [PMID: 24631577 DOI: 10.1053/j.gastro.2014.03.005]
13 Piroth L, Pechinot A, Minello A, Jaulhac B, Patry I, Hadou 
T, Hansmann Y, Rabaud C, Chavanet P, Neuwirth C. Bacterial 
epidemiology and antimicrobial resistance in ascitic fluid: a 2-year 
retrospective study. Scand J Infect Dis 2009; 41: 847-851 [PMID: 
19922067 DOI: 10.3109/00365540903244535]
14 Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung 
DR, Koh KC, Lee NY, Song JH, Peck KR. Clinical significance 
and outcome of nosocomial acquisition of spontaneous bacterial 
peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009; 48: 
1230-1236 [PMID: 19302016 DOI: 10.1086/597585]
15 Lee YY, Tee HP, Mahadeva S. Role of prophylactic antibiotics in 
cirrhotic patients with variceal bleeding. World J Gastroenterol 
2014; 20: 1790-1796 [PMID: 24587656 DOI: 10.3748/wjg.v20.
i7.1790]
16 Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: 
recent guidelines and beyond. Gut 2012; 61: 297-310 [PMID: 
22147550 DOI: 10.1136/gutjnl-2011-300779]
17 Wiest R, Lawson M, Geuking M. Pathological bacterial 
translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209 [PMID: 
23993913 DOI: 10.1016/j.jhep.2013.07.044]
18 Guarner C, González-Navajas JM, Sánchez E, Soriando G, 
Francés R, Chiva M, Zapater P, Benlloch S, Muñoz C, Pascual S, 
Balanzó J, Pérez-Mateo M, Such J. The detection of bacterial DNA 
in blood of rats with CCl4-induced cirrhosis with ascites represents 
episodes of bacterial translocation. Hepatology 2006; 44: 633-639 
[PMID: 16941689 DOI: 10.1002/hep.21286]
19 Llovet JM, Bartolí R, March F, Planas R, Viñado B, Cabré E, Arnal 
J, Coll P, Ausina V, Gassull MA. Translocated intestinal bacteria 
cause spontaneous bacterial peritonitis in cirrhotic rats: molecular 
epidemiologic evidence. J Hepatol 1998; 28: 307-313 [PMID: 
9580278 DOI: 10.1016/0168-8278(88)80018-7]
20 Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster 
J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés 
J. Bacterial translocation of enteric organisms in patients with 
cirrhosis. J Hepatol 2001; 34: 32-37 [PMID: 11211904 DOI: 
10.1016/S0168-8278(00)00013-1]
21 Albillos A, de la Hera A, González M, Moya JL, Calleja JL, 
Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased 
lipopolysaccharide binding protein in cirrhotic patients with marked 
immune and hemodynamic derangement. Hepatology 2003; 37: 
208-217 [PMID: 12500206 DOI: 10.1053/jhep.2003.50038]
22 Such J, Francés R, Muñoz C, Zapater P, Casellas JA, Cifuentes 
A, Rodríguez-Valera F, Pascual S, Sola-Vera J, Carnicer F, Uceda 
F, Palazón JM, Pérez-Mateo M. Detection and identification of 
bacterial DNA in patients with cirrhosis and culture-negative, 
nonneutrocytic ascites. Hepatology 2002; 36: 135-141 [PMID: 
12085357 DOI: 10.1053/jhep.2002.33715]
23 Rogers GB, van der Gast CJ, Bruce KD, Marsh P, Collins JE, 
Sutton J, Wright M. Ascitic microbiota composition is correlated 
with clinical severity in cirrhosis with portal hypertension. PLoS 
One 2013; 8: e74884 [PMID: 24086392 DOI: 10.1371/journal.
pone.0074884]
24 Ashley BD, Noone M, Dwarakanath AD, Malnick H. Fatal 
Pasteurella dagmatis peritonitis and septicaemia in a patient with 
cirrhosis: a case report and review of the literature. J Clin Pathol 
2004; 57: 210-212 [PMID: 14747455 DOI: 10.1136/jcp.2003.7419]
25 Lutz P, Parcina M, Bekeredjian-Ding I, Hoerauf A, Strassburg 
CP, Spengler U. Spontaneous bacterial peritonitis by Pasteurella 
multocida under treatment with rifaximin. Infection 2014; 42: 
175-177 [PMID: 23526308 DOI: 10.1007/s15010-013-0449-4]
26 Lee YL, Shih SD, Weng YJ, Chen C, Liu CE. Fatal spontaneous 
bacterial peritonitis and necrotizing fasciitis with bacteraemia 
caused by Bacillus cereus in a patient with cirrhosis. J Med 
Microbiol 2010; 59: 242-244 [PMID: 19850708 DOI: 10.1099/
jmm.0.011056-0]
27 Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier 
E, Yao J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy 
SP, Leonard P, Yuan C, Ding W, Chen Y, Hu X, Zheng B, Qian G, 
Xu W, Ehrlich SD, Zheng S, Li L. Alterations of the human gut 
microbiome in liver cirrhosis. Nature 2014; 513: 59-64 [PMID: 
25079328 DOI: 10.1038/nature13568]
28 Seki E, Schnabl B. Role of innate immunity and the microbiota in 
liver fibrosis: crosstalk between the liver and gut. J Physiol 2012; 590: 
447-458 [PMID: 22124143 DOI: 10.1113/jphysiol.2011.219691]
29 Su GL, Rahemtulla A, Thomas P, Klein RD, Wang SC, Nanji AA. 
CD14 and lipopolysaccharide binding protein expression in a rat 
model of alcoholic liver disease. Am J Pathol 1998; 152: 841-849 
[PMID: 9502426]
30 Nakatani Y, Fukui H, Kitano H, Nagamoto I, Tsujimoto T, 
Kuriyama S, Kikuchi E, Hoppou K, Tsujii T. Endotoxin clearance 
and its relation to hepatic and renal disturbances in rats with liver 
cirrhosis. Liver 2001; 21: 64-70 [PMID: 11169075 DOI: 10.1034/
j.1600-0676.2001.210110.x]
31 Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch 
BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, 
Vogelsang H. Non-selective betablocker therapy decreases intestinal 
permeability and serum levels of LBP and IL-6 in patients with 
cirrhosis. J Hepatol 2013; 58: 911-921 [PMID: 23262249 DOI: 
10.1016/j.jhep.2012.12.011]
32 Fukui H, Matsumoto M, Tsujita S, Takaya A, Kojima H, 
Matsumura M, Tsujii T. Plasma endotoxin concentration and 
endotoxin binding capacity of plasma acute phase proteins in 
cirrhotics with variceal bleeding: an analysis by new methods. J 
Gastroenterol Hepatol 1994; 9: 582-586 [PMID: 7532449 DOI: 
10.1111/j.1440-1746.1994.tb01565.x]
33 El-Naggar MM, Khalil el-SA, El-Daker MA, Salama MF. Bacterial 
DNA and its consequences in patients with cirrhosis and culture-
negative, non-neutrocytic ascites. J Med Microbiol 2008; 57: 
1533-1538 [PMID: 19018026 DOI: 10.1099/jmm.0.2008/001867-0]
34 Jain L, Sharma BC, Sharma P, Srivastava S, Agrawal A, Sarin 
SK. Serum endotoxin and inflammatory mediators in patients with 
cirrhosis and hepatic encephalopathy. Dig Liver Dis 2012; 44: 
1027-1031 [PMID: 22883217 DOI: 10.1016/j.dld.2012.07.002]
35 Schnabl B, Brenner DA. Interactions between the intestinal 
microbiome and liver diseases. Gastroenterology 2014; 146: 
1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
36 Pijls KE, Jonkers DM, Elamin EE, Masclee AA, Koek GH. 
Intestinal epithelial barrier function in liver cirrhosis: an extensive 
review of the literature. Liver Int 2013; 33: 1457-1469 [PMID: 
23879434 DOI: 10.1111/liv.12271]
37 Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune 
dysfunction in cirrhosis. World J Gastroenterol 2014; 20: 2564-2577 
[PMID: 24627592 DOI: 10.3748/wjg.v20.i10.2564]
38 Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial 
overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 
2007; 3: 112-122 [PMID: 21960820]
39 Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth 
in cirrhosis is related to the severity of liver disease. Aliment 
Pharmacol Ther 2009; 29: 1273-1281 [PMID: 19302262 DOI: 
10.1111/j.1365-2036.2009.03994.x]
40 Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen 
AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small 
intestinal bacterial overgrowth in human cirrhosis is associated with 
Lutz P et al . Spontaneous bacterial peritonitis: Clinical challenges
311 March 27, 2015|Volume 7|Issue 3|WJH|www.wjgnet.com
systemic endotoxemia. Am J Gastroenterol 2002; 97: 2364-2370 
[PMID: 12358257 DOI: 10.1111/j.1572-0241.2002.05791.x]
41 Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White 
MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic 
mucosal microbiome differs from stool microbiome in cirrhosis and 
hepatic encephalopathy and is linked to cognition and inflammation. 
Am J Physiol Gastrointest Liver Physiol 2012; 303: G675-G685 
[PMID: 22821944 DOI: 10.1152/ajpgi.00152.2012]
42 Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, 
Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, 
White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. 
Modulation of the metabiome by rifaximin in patients with cirrhosis 
and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042 
[PMID: 23565181 DOI: 10.1371/journal.pone.0060042]
43 Kao CY, Lin WH, Tseng CC, Wu AB, Wang MC, Wu JJ. The 
complex interplay among bacterial motility and virulence factors 
in different Escherichia coli infections. Eur J Clin Microbiol 
Infect Dis 2014; 33: 2157-2162 [PMID: 24957011 DOI: 10.1007/
s10096-014-2171-2]
44 Soriano G, Coll P, Guarner C, Such J, Sánchez F, Prats G, Vilardell 
F. Escherichia coli capsular polysaccharide and spontaneous 
bacterial peritonitis in cirrhosis. Hepatology 1995; 21: 668-673 
[PMID: 7875665 DOI: 10.1002/hep.1840210311]
45 Wang MC, Lin WH, Tseng CC, Wu AB, Teng CH, Yan JJ, Wu JJ. 
Role of K1 capsule antigen in cirrhotic patients with Escherichia 
coli spontaneous bacterial peritonitis in southern Taiwan. Eur J Clin 
Microbiol Infect Dis 2013; 32: 407-412 [PMID: 23052990 DOI: 
10.1007/s10096-012-1757-9]
46 Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. 
Bacterial translocation and changes in the intestinal microbiome 
in mouse models of liver disease. J Hepatol 2012; 56: 1283-1292 
[PMID: 22326468 DOI: 10.1016/j.jhep.2012.01.019]
47 White JS, Hoper M, Parks RW, Clements WD, Diamond T. Patterns 
of bacterial translocation in experimental biliary obstruction. J 
Surg Res 2006; 132: 80-84 [PMID: 16154151 DOI: 10.1016/
j.jss.2005.07.026]
48 Inamura T, Miura S, Tsuzuki Y, Hara Y, Hokari R, Ogawa 
T, Teramoto K, Watanabe C, Kobayashi H, Nagata H, Ishii 
H. Alteration of intestinal intraepithelial lymphocytes and 
increased bacterial translocation in a murine model of cirrhosis. 
Immunol Lett 2003; 90: 3-11 [PMID: 14611901 DOI: 10.1016/
j.imlet.2003.05.002]
49 Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. 
Intestinal permeability in liver cirrhosis: relationship with severe septic 
complications. Eur J Gastroenterol Hepatol 1999; 11: 755-759 [PMID: 
10445796 DOI: 10.1097/00042737-199907000-00013]
50 Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio 
JR, Girona E, Gutiérrez A, Carnices F, Palazón JM, Sola-Vera J, 
Pérez-Mateo M. Intestinal permeability is increased in patients with 
advanced cirrhosis. Hepatogastroenterology 2003; 50: 1482-1486 
[PMID: 14571769]
51 Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear 
bile acid receptor FXR paradigm. Nucl Recept Signal 2010; 8: e005 
[PMID: 21383957 DOI: 10.1621/nrs.08005]
52 Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu 
RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer 
SA. Regulation of antibacterial defense in the small intestine by 
the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103: 
3920-3925 [PMID: 16473946 DOI: 10.1073/pnas.0509592103]
53 Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein 
S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W. 
Obeticholic acid, a farnesoid X receptor agonist, improves portal 
hypertension by two distinct pathways in cirrhotic rats. Hepatology 
2014; 59: 2286-2298 [PMID: 24259407 DOI: 10.1002/hep.26939]
54 Lutz P, Berger C, Langhans B, Grünhage F, Appenrodt B, 
Nattermann J, Lammert F, Hoerauf A, Sauerbruch T, Strassburg CP, 
Spengler U, Nischalke HD. A farnesoid X receptor polymorphism 
predisposes to spontaneous bacterial peritonitis. Dig Liver Dis 2014; 
46: 1047-1050 [PMID: 25086996 DOI: 10.1016/j.dld.2014.07.008]
55 Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, 
Sauerbruch T, Lammert F. Nucleotide-binding oligomerization 
domain containing 2 (NOD2) variants are genetic risk factors 
for death and spontaneous bacterial peritonitis in liver cirrhosis. 
Hepatology 2010; 51: 1327-1333 [PMID: 20087966 DOI: 10.1002/
hep.23440]
56 Bruns T, Peter J, Reuken PA, Grabe DH, Schuldes SR, Brenmoehl 
J, Schölmerich J, Wiest R, Stallmach A. NOD2 gene variants are a 
risk factor for culture-positive spontaneous bacterial peritonitis and 
monomicrobial bacterascites in cirrhosis. Liver Int 2012; 32: 223-230 
[PMID: 21745302 DOI: 10.1111/j.1478-3231.2011.02561.x]
57 Strober W, Watanabe T. NOD2, an intracellular innate immune 
sensor involved in host defense and Crohn’s disease. Mucosal 
Immunol 2011; 4: 484-495 [PMID: 21750585 DOI: 10.1038/
mi.2011.29]
58 Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, 
Patch D, Burroughs AK. beta-Blockers protect against spontaneous 
bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver 
Int 2009; 29: 1189-1193 [PMID: 19508620 DOI: 10.1111/
j.1478-3231.2009.02038.x]
59 Rössle M. TIPS: 25 years later. J Hepatol 2013; 59: 1081-1093 
[PMID: 23811307 DOI: 10.1016/j.jhep.2013.06.014]
60 Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular 
intrahepatic portosystemic shunt for refractory ascites: a meta-
analysis of individual patient data. Gastroenterology 2007; 133: 
825-834 [PMID: 17678653 DOI: 10.1053/j.gastro.2007.06.020]
61 Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann 
M, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler 
U, Appenrodt B. Toll-like receptor (TLR) 2 promoter and intron 2 
polymorphisms are associated with increased risk for spontaneous 
bacterial peritonitis in liver cirrhosis. J Hepatol 2011; 55: 
1010-1016 [PMID: 21356257 DOI: 10.1016/j.jhep.2011.02.022]
62 Gäbele E, Mühlbauer M, Paulo H, Johann M, Meltzer C, Leidl 
F, Wodarz N, Wiest R, Schölmerich J, Hellerbrand C. Analysis of 
monocyte chemotactic protein-1 gene polymorphism in patients 
with spontaneous bacterial peritonitis. World J Gastroenterol 2009; 
15: 5558-5562 [PMID: 19938194 DOI: 10.3748/wjg.15.5558]
63 Salama MK, Sabry D, Al-Ghussein MA, Ahmed R, AbdAllah 
S, Taha FM, Fathy W, Wadie MS, Nabih M, Abul-Fotouh A, 
Darwish T. Molecular detection of monocyte chemotactic protein-1 
polymorphism in spontaneous bacterial peritonitis patients. World 
J Gastroenterol 2014; 20: 11793-11799 [PMID: 25206284 DOI: 
10.3748/wjg.v20.i33.11793]
64 Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen 
recognition. Int Immunol 2009; 21: 317-337 [PMID: 19246554 
DOI: 10.1093/intimm/dxp017]
65 Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, Gladue 
R, Rollins B. In vivo properties of monocyte chemoattractant 
protein-1. J Leukoc Biol 1997; 62: 577-580 [PMID: 9365111]
66 Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 
gene regulatory region that influences MCP-1 expression. Biochem 
Biophys Res Commun 1999; 259: 344-348 [PMID: 10362511 DOI: 
10.1006/bbrc.1999.0796]
67 Taylor NJ, Manakkat Vijay GK, Abeles RD, Auzinger G, Bernal 
W, Ma Y, Wendon JA, Shawcross DL. The severity of circulating 
neutrophil dysfunction in patients with cirrhosis is associated with 
90-day and 1-year mortality. Aliment Pharmacol Ther 2014; 40: 
705-715 [PMID: 25060167 DOI: 10.1111/apt.12886]
68 Ono Y, Watanabe T, Matsumoto K, Ito T, Kunii O, Goldstein E. 
Opsonophagocytic dysfunction in patients with liver cirrhosis and 
low responses to tumor necrosis factor-alpha and lipopolysaccharide 
in patients’ blood. J Infect Chemother 2004; 10: 200-207 [PMID: 
15365859 DOI: 10.1007/s10156-004-0321-7]
69 Schirren CA, Jung MC, Zachoval R, Diepolder H, Hoffmann R, 
Riethmüller G, Pape GR. Analysis of T cell activation pathways 
in patients with liver cirrhosis, impaired delayed hypersensitivity 
and other T cell-dependent functions. Clin Exp Immunol 1997; 
108: 144-150 [PMID: 9097923 DOI: 10.1046/j.1365-2249.1997.
d01-985.x]
70 Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shiina M, Inoue J, 
Tamai K, Ninomiya M, Shimosegawa T. Branched chain amino 
Lutz P et al . Spontaneous bacterial peritonitis: Clinical challenges
312 March 27, 2015|Volume 7|Issue 3|WJH|www.wjgnet.com
acids enhance the maturation and function of myeloid dendritic 
cells ex vivo in patients with advanced cirrhosis. Hepatology 2009; 
50: 1936-1945 [PMID: 19885880 DOI: 10.1002/hep.23248]
71 Tapia-Abellán A, Martínez-Esparza M, Ruiz-Alcaraz AJ, Hernández-
Caselles T, Martínez-Pascual C, Miras-López M, Such J, Francés R, 
García-Peñarrubia P. The peritoneal macrophage inflammatory profile 
in cirrhosis depends on the alcoholic or hepatitis C viral etiology and 
is related to ERK phosphorylation. BMC Immunol 2012; 13: 42 [PMID: 
22866973 DOI: 10.1186/1471-2172-13-42]
72 Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant 
of spontaneous bacterial peritonitis. Hepatology 1990; 12: 710-715 
[PMID: 2210672 DOI: 10.1002/hep.1840120415]
73 Sugihara T, Koda M, Maeda Y, Matono T, Nagahara T, Mandai M, 
Ueki M, Murawaki Y. Rapid identification of bacterial species with 
bacterial DNA microarray in cirrhotic patients with spontaneous 
bacterial peritonitis. Intern Med 2009; 48: 3-10 [PMID: 19122350 
DOI: 10.2169/internalmedicine.48.1539]
74 Bruns T, Sachse S, Straube E, Assefa S, Herrmann A, Hagel 
S, Lehmann M, Stallmach A. Identification of bacterial DNA in 
neutrocytic and non-neutrocytic cirrhotic ascites by means of a 
multiplex polymerase chain reaction. Liver Int 2009; 29: 1206-1214 
[PMID: 19602138 DOI: 10.1111/j.1478-3231.2009.02073.x]
75 Appenrodt B, Lehmann LE, Thyssen L, Gentemann M, Rabe 
C, Molitor E, Trebicka J, Stüber F, Sauerbruch T. Is detection 
of bacterial DNA in ascitic fluid of clinical relevance? Eur J 
Gastroenterol Hepatol 2010; 22: 1487-1494 [PMID: 21048463 
DOI: 10.1097/MEG.0b013e328340c43a]
76 Soriano G, Esparcia O, Montemayor M, Guarner-Argente C, 
Pericas R, Torras X, Calvo N, Román E, Navarro F, Guarner C, 
Coll P. Bacterial DNA in the diagnosis of spontaneous bacterial 
peritonitis. Aliment Pharmacol Ther 2011; 33: 275-284 [PMID: 
21083594 DOI: 10.1111/j.1365-2036.2010.04506.x]
77 Enomoto H, Inoue S, Matsuhisa A, Aizawa N, Imanishi H, Saito 
M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Shimomura 
S, Iijima H, Nakamura H, Nishiguchi S. Development of a new in 
situ hybridization method for the detection of global bacterial DNA 
to provide early evidence of a bacterial infection in spontaneous 
bacterial peritonitis. J Hepatol 2012; 56: 85-94 [PMID: 21835139 
DOI: 10.1016/j.jhep.2011.06.025]
78 Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, 
Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert 
F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, 
Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs 
A, Ginès P. Bacterial infections in cirrhosis: a position statement 
based on the EASL Special Conference 2013. J Hepatol 2014; 60: 
1310-1324 [PMID: 24530646 DOI: 10.1016/j.jhep.2014.01.024]
79 Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota 
R, Ariza J, Xiol X. Risk factors for resistance to ceftriaxone and 
its impact on mortality in community, healthcare and nosocomial 
spontaneous bacterial peritonitis. J Hepatol 2012; 56: 825-832 
[PMID: 22173153 DOI: 10.1016/j.jhep.2011.11.010]
80 Mendler MH, Agarwal A, Trimzi M, Madrigal E, Tsushima M, 
Joo E, Santiago M, Flores E, David G, Workman A, Runyon B. A 
new highly sensitive point of care screen for spontaneous bacterial 
peritonitis using the leukocyte esterase method. J Hepatol 2010; 53: 
477-483 [PMID: 20646775 DOI: 10.1016/j.jhep.2010.04.011]
81 Burri E, Schulte F, Muser J, Meier R, Beglinger C. Measurement of 
calprotectin in ascitic fluid to identify elevated polymorphonuclear 
cell count. World J Gastroenterol 2013; 19: 2028-2036 [PMID: 
23599621 DOI: 10.3748/wjg.v19.i13.2028]
82 Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol 
L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. 
Effect of intravenous albumin on renal impairment and mortality 
in patients with cirrhosis and spontaneous bacterial peritonitis. N 
Engl J Med 1999; 341: 403-409 [PMID: 10432325 DOI: 10.1056/
NEJM199908053410603]
83 Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T. 
Emergence of spontaneous bacterial peritonitis due to enterococci 
- risk factors and outcome in a 12-year retrospective study. Aliment 
Pharmacol Ther 2012; 35: 1199-1208 [PMID: 22449290 DOI: 
10.1111/j.1365-2036.2012.05076.x]
84 Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W. Failure 
of current antibiotic first-line regimens and mortality in hospitalized 
patients with spontaneous bacterial peritonitis. Infection 2009; 37: 
2-8 [PMID: 19169633 DOI: 10.1007/s15010-008-8060-9]
85 Fernández J, Gustot T. Management of bacterial infections in 
cirrhosis. J Hepatol 2012; 56 Suppl 1: S1-12 [PMID: 22300459 
DOI: 10.1016/S0168-8278(12)60002-6]
86 Piano S, Salinas F, Morando F, Cavalin M, Romano A, Rosi S, 
Stanco M, Fasolato S, Sticca A, Senzolo M, Burra P, Gringeri E, 
Cillo U, Gatta A, Angeli P. Poster Session 1: Infections and Acute 
on Chronic Liver Failure. Abstract 574: The empirical antibiotic 
treatment of nosocomial spontaneous bacterial peritonitis in 
patients with decompensated liver cirrhosis: results of a randomized 
controlled clinical trial. Hepatology 2014; 60: 478A-501A [DOI: 
10.1002/hep.27505]
87 Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon 
MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, 
Thacker LR, Bajaj JS. New consensus definition of acute kidney 
injury accurately predicts 30-day mortality in patients with cirrhosis 
and infection. Gastroenterology 2013; 145: 1280128-8.e1 [PMID: 
23999172 DOI: 10.1053/j.gastro.2013.08.051]
88 Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla 
R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin vs 
ceftriaxone in the prophylaxis of infections in patients with 
advanced cirrhosis and hemorrhage. Gastroenterology 2006; 
131: 1049-1056; quiz 1285 [PMID: 17030175 DOI: 10.1053/
j.gastro.2006.07.010]
89 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-
Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients 
with upper gastrointestinal bleeding. Cochrane Database Syst Rev 
2010; (9): CD002907 [PMID: 20824832 DOI: 10.1002/14651858.
CD002907.pub2]
90 Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, 
Coll S, Oliver MI. Risk factors for spontaneous bacterial peritonitis 
in cirrhotic patients with ascites. Gastroenterology 1993; 104: 
1133-1138 [PMID: 8462803]
91 Such J, Guarner C, Enriquez J, Rodriguez JL, Seres I, Vilardell F. 
Low C3 in cirrhotic ascites predisposes to spontaneous bacterial 
peritonitis. J Hepatol 1988; 6: 80-84 [PMID: 3279108 DOI: 
10.1016/S0168-8278(88)80465-3]
92 Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, 
Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, 
Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis 
delays hepatorenal syndrome and improves survival in cirrhosis. 
Gastroenterology 2007; 133: 818-824 [PMID: 17854593 DOI: 
10.1053/j.gastro.2007.06.065]
93 Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné 
M, Miranda ML, Llach J, Salmerón JM. Norfloxacin prevents 
spontaneous bacterial peritonitis recurrence in cirrhosis: results 
of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 
716-724 [PMID: 2210673 DOI: 10.1002/hep.1840120416]
94 Segarra-Newnham M, Henneman A. Antibiotic prophylaxis for 
prevention of spontaneous bacterial peritonitis in patients without 
gastrointestinal bleeding. Ann Pharmacother 2010; 44: 1946-1954 
[PMID: 21098755 DOI: 10.1345/aph.1P317]
95 Tandon P, Delisle A, Topal JE, Garcia-Tsao G. High prevalence 
of antibiotic-resistant bacterial infections among patients with 
cirrhosis at a US liver center. Clin Gastroenterol Hepatol 2012; 10: 
1291-1298 [PMID: 22902776 DOI: 10.1016/j.cgh.2012.08.017]
96 Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, 
Rolston DD, Sferra TJ, Hernandez AV. Acid-suppressive therapy 
is associated with spontaneous bacterial peritonitis in cirrhotic 
patients: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 
235-242 [PMID: 23190338 DOI: 10.1111/jgh.12065]
97 Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann 
RG, Sanyal AJ, Saeian K. Association of proton pump inhibitor 
therapy with spontaneous bacterial peritonitis in cirrhotic patients 
with ascites. Am J Gastroenterol 2009; 104: 1130-1134 [PMID: 
19337238 DOI: 10.1038/ajg.2009.80]
Lutz P et al . Spontaneous bacterial peritonitis: Clinical challenges
313 March 27, 2015|Volume 7|Issue 3|WJH|www.wjgnet.com
98 Garcia-Martinez I, Francés R, Zapater P, Giménez P, Gómez-
Hurtado I, Moratalla A, Lozano-Ruiz B, Bellot P, González-
Navajas JM, Such J. Use of proton pump inhibitors decrease 
cellular oxidative burst in patients with decompensated cirrhosis. J 
Gastroenterol Hepatol 2015; 30: 147-154 [PMID: 25039465 DOI: 
10.1111/jgh.12667]
99 Bauer TM, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha 
H, Aponte JJ, Pelz K, Kist M, Blum HE. Small intestinal bacterial 
overgrowth in patients with cirrhosis: prevalence and relation with 
spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 
2962-2967 [PMID: 11693333 DOI: 10.1111/j.1572-0241.2001.04668.x]
100 Zhang W, Gu Y, Chen Y, Deng H, Chen L, Chen S, Zhang G, Gao 
Z. Intestinal flora imbalance results in altered bacterial translocation 
and liver function in rats with experimental cirrhosis. Eur J 
Gastroenterol Hepatol 2010; 22: 1481-1486 [PMID: 20739895 
DOI: 10.1097/MEG.0b013e32833eb8b0]
101 Sánchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, 
Sancho-Bru P, Oms R, Mirelis B, Juárez C, Guarner C, Soriano 
G. VSL#3 probiotic treatment decreases bacterial translocation in 
rats with carbon tetrachloride-induced cirrhosis. Liver Int 2015; 35: 
735-745 [PMID: 24750552 DOI: 10.1111/liv.12566]
102 Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-
Cohen Y. Probiotics for patients with compensated liver cirrhosis: a 
double-blind placebo-controlled study. Nutrition 2011; 27: 177-181 
[PMID: 20452184 DOI: 10.1016/j.nut.2010.01.006]
103 Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin 
does not improve efficacy in the prevention of spontaneous 
bacterial peritonitis: a double-blind placebo-controlled randomized-
controlled trial. Eur J Gastroenterol Hepatol 2012; 24: 831-839 
[PMID: 22522141 DOI: 10.1097/MEG.0b013e3283537d61]
104 Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: 
pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl 
1: 36-66 [PMID: 15855748 DOI: 10.1159/000081990]
105 Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy 
CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, 
Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes 
WP. Rifaximin treatment in hepatic encephalopathy. N Engl J 
Med 2010; 362: 1071-1081 [PMID: 20335583 DOI: 10.1056/
NEJMoa0907893]
106 Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. 
conventional oral therapy for hepatic encephalopathy: a meta-
analysis. World J Gastroenterol 2012; 18: 767-777 [PMID: 
22371636 DOI: 10.3748/wjg.v18.i8.767]
107 DuPont HL, Jiang ZD. Influence of rifaximin treatment on the 
susceptibility of intestinal Gram-negative flora and enterococci. 
Clin Microbiol Infect 2004; 10: 1009-1011 [PMID: 15522005 DOI: 
10.1111/j.1469-0691.2004.00997.x]
108 Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, 
Karamanolis DG, Ladas SD. Long-term administration of rifaximin 
improves the prognosis of patients with decompensated alcoholic 
cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-455 [PMID: 
23216382 DOI: 10.1111/jgh.12070]
109 Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, 
Lopez R, Hazratjee N, Smith T, Zein NN. The role of rifaximin 
in the primary prophylaxis of spontaneous bacterial peritonitis in 
patients with liver cirrhosis. J Clin Gastroenterol 2012; 46: 709-715 
[PMID: 22878533 DOI: 10.1097/MCG.0b013e3182506dbb]
110 Lutz P, Parcina M, Bekeredjian-Ding I, Nischalke HD, Nattermann 
J, Sauerbruch T, Hoerauf A, Strassburg CP, Spengler U. Impact 
of rifaximin on the frequency and characteristics of spontaneous 
bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS 
One 2014; 9: e93909 [PMID: 24714550 DOI: 10.1371/journal.
pone.0093909]
111 Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, 
Salzer HJ, Krause R. Rifaximin intake leads to emergence of 
rifampin-resistant staphylococci. J Infect 2011; 62: 34-38 [PMID: 
21073894 DOI: 10.1016/j.jinf.2010.11.004]
112 Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel 
J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia 
coli associated with inflammatory bowel disease correlates with 
prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-
β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents 
Chemother 2013; 57: 811-817 [PMID: 23183443 DOI: 10.1128/
AAC.02163-12]
113 Carman RJ, Boone JH, Grover H, Wickham KN, Chen L. In 
vivo selection of rifamycin-resistant Clostridium difficile during 
rifaximin therapy. Antimicrob Agents Chemother 2012; 56: 
6019-6020 [PMID: 22908175 DOI: 10.1128/AAC.00974-12]
114 Silveira MG, Lindor KD. Obeticholic acid and budesonide for the 
treatment of primary biliary cirrhosis. Expert Opin Pharmacother 
2014; 15: 365-372 [PMID: 24382005 DOI: 10.1517/14656566.201
4.873404]
115 Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, 
Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon 
P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X 
receptor agonist obeticholic acid in patients with type 2 diabetes 
and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 
574-582.e1 [PMID: 23727264 DOI: 10.1053/j.gastro.2013.05.042]
116 Obstein KL, Campbell MS, Reddy KR, Yang YX. Association 
between model for end-stage liver disease and spontaneous bacterial 
peritonitis. Am J Gastroenterol 2007; 102: 2732-2736 [PMID: 
17714556 DOI: 10.1111/j.1572-0241.2007.01485.x]
117 Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, 
Gines P, Rodes J. Cefotaxime is more effective than is ampicillin-
tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 
457-462 [PMID: 3888810 DOI: 10.1002/hep.1840050319]
118 Rimola A, Salmerón JM, Clemente G, Rodrigo L, Obrador A, 
Miranda ML, Guarner C, Planas R, Solá R, Vargas V. Two different 
dosages of cefotaxime in the treatment of spontaneous bacterial 
peritonitis in cirrhosis: results of a prospective, randomized, 
multicenter study. Hepatology 1995; 21: 674-679 [PMID: 7875666 
DOI: 10.1002/hep.1840210312]
119 Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, 
Marco F, Guarner C, Forné M, Planas R, Bañares R, Castells L, 
Jimenez De Anta MT, Arroyo V, Rodés J. Randomized, comparative 
study of oral ofloxacin versus intravenous cefotaxime in spontaneous 
bacterial peritonitis. Gastroenterology 1996; 111: 1011-1017 [PMID: 
8831596 DOI: 10.1016/S0016-5085(96)70069-0]
120 Ricart E, Soriano G, Novella MT, Ortiz J, Sàbat M, Kolle L, 
Sola-Vera J, Miñana J, Dedéu JM, Gómez C, Barrio JL, Guarner 
C. Amoxicillin-clavulanic acid versus cefotaxime in the therapy 
of bacterial infections in cirrhotic patients. J Hepatol 2000; 32: 
596-602 [PMID: 10782908 DOI: 10.1016/S0168-8278(00)80221-4]
121 Terg R, Cobas S, Fassio E, Landeira G, Ríos B, Vasen W, Abecasis 
R, Ríos H, Guevara M. Oral ciprofloxacin after a short course 
of intravenous ciprofloxacin in the treatment of spontaneous 
bacterial peritonitis: results of a multicenter, randomized study. 
J Hepatol 2000; 33: 564-569 [PMID: 11059861 DOI: 10.1016/
S0168-8278(00)80008-2]
122 Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enríquez 
J, Vilardell F. Selective intestinal decontamination prevents 
spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 
477-481 [PMID: 1985045]
123 Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-
sulfamethoxazole for the prevention of spontaneous bacterial 
peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 
122: 595-598 [PMID: 7887554 DOI: 10.7326/0003-4819-122-8-19
9504150-00007]
124 Grangé JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, 
Blanc P, Richardet JP, Vinel JP, Delisle F, Fischer D, Flahault A, 
Amiot X. Norfloxacin primary prophylaxis of bacterial infections 
in cirrhotic patients with ascites: a double-blind randomized trial. 
J Hepatol 1998; 29: 430-436 [PMID: 9764990 DOI: 10.1016/
S0168-8278(98)80061-5]
125 Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris 
JC, Fratte S, Bohn B, Kitmacher P, Stahl JP. Ciprofloxacin and 
long-term prevention of spontaneous bacterial peritonitis: results 
of a prospective controlled trial. Hepatology 1995; 22: 1171-1174 
[PMID: 7557868]
126 Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, Coll 
Lutz P et al . Spontaneous bacterial peritonitis: Clinical challenges
314 March 27, 2015|Volume 7|Issue 3|WJH|www.wjgnet.com
S, Sàbat M, Vila MC, Guarner C, Vilardell F. Continuous versus 
inpatient prophylaxis of the first episode of spontaneous bacterial 
peritonitis with norfloxacin. Hepatology 1997; 25: 532-536 [PMID: 
9049193 DOI: 10.1002/hep.510250306]
127 Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, 
Landeira C, Romero G, Dominguez N, Muñoz A, Levi D, Miguez C, 
Abecasis R. Ciprofloxacin in primary prophylaxis of spontaneous 
bacterial peritonitis: a randomized, placebo-controlled study. J 
Hepatol 2008; 48: 774-779 [PMID: 18316137 DOI: 10.1016/
j.jhep.2008.01.024]
P- Reviewer: Al-Shamma S, Kaya M, Liaskou E, Sira MM 
S- Editor: Tian YL    L- Editor: A    E- Editor: Wu HL
Lutz P et al . Spontaneous bacterial peritonitis: Clinical challenges
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
